Summary
As the world continues to deal with COVID-19, economies are moving into recession, under multiple adverse factors, the GDP of European and American countries in the second quarter suffered a historical contraction. At an annualized rate, the US GDP fell by 32.9% month on month, while the overall GDP of the euro zone fell by 12.1%.
Moreover, the economic prospects of Europe and the United States in the third quarter under the epidemic situation are hardly optimistic. The resumption of work and production not only brought economic data back, but also triggered a rebound in the epidemic situation. At present, the United States is still the 'epicenter' of the global epidemic. The total number of confirmed cases has exceeded 4.8 million, and the epidemic situation in some European countries has also rebounded. Affected by this, more than 20 states in the United States have announced the suspension or withdrawal of part of the economic restart plan. Britain and Italy have also decided to extend the state of emergency. The rebound of the epidemic situation has posed considerable risks to the economic prospects of Europe and the United States.
In the second quarter of this year, US GDP shrank by 9.5% on a month on month basis, or 32.9% at an annual rate, the largest decline since the 1940s. Data show that the sharp decline in personal consumption is the main drag on the U.S. GDP growth in the second quarter.
Compared with the United States, Europe's economic contraction in the second quarter was smaller, but it was also the lowest on record, with Germany and France contracting more than 10%. According to the data released by the Federal Bureau of statistics, Germany's GDP fell by 10.1% in the second quarter after adjusting for prices, seasons and working days, the largest decline since the quarterly economic data were available in 1970.
Thanks to the effective control and policy support of the new epidemic, China's economy rebounded sharply in the second quarter. The growth rate of manufacturing industry, which accounted for about 28% of GDP, rebounded sharply to 4.4% from the negative value in the first quarter. Chinese original equipment manufacturers (OEMs) and suppliers are ramping up production. And there are increased investments in digital footprints in manufacturing. OEMs in other parts of the world are offering incentives to drive sales. XYZResearch published a report for global Oncology Biosimilar market in this environment.
In terms of revenue, this research report indicated that the global Oncology Biosimilar market was valued at USD XXX million in 2019, and it is expected to reach a value of USD XXX million by 2026, at a CAGR of XX % over the forecast period 2021-2026. Correspondingly, the forecast analysis of Oncology Biosimilar industry comprises of China, USA, Japan, India, Korea and South America, with the production and revenue data in each of the sub-segments.
The Biocon aims at producing XX Oncology Biosimilar in 2020, with XX % production to take place in global market, Celltrion Inc. accounts for a volume share of XX %.
Regional Segmentation (Value; Revenue, USD Million, 2015 - 2026) of Oncology Biosimilar Market by XYZResearch Include
- China
- EU
- USA
- Japan
- India
- Southeast Asia
- South America
Competitive Analysis; Who are the Major Players in Oncology Biosimilar Market?
- Biocon
- Celltrion Inc.
- Dr. Reddy's Laboratories
- Intas Pharmaceuticals Ltd.
- STADA Arzneimittel AG
- Pfizer Inc.
- Apotex Inc.
- Teva Pharmaceutical Industries Ltd.
- Sandoz International GmbH
- BIOCAD
- Mylan
- F Hoffmann-La Roche
- ...
Major Type of Oncology Biosimilar Covered in XYZResearch report:
- Lung Cancer
- Colorectal Cancer
- Cervical Cancer
- Breast Cancer
- Kidney Cancer
- Stomach Cancer
- Brain Cancer
- Others
Application Segments Covered in XYZResearch Market
- Hospital Pharmacies
- Online Pharmacies
- Retail Pharmacies
- Others
For any other requirements, please feel free to contact us and we will provide you customized report.
Post-pandemic Era - Global Oncology Biosimilar Market (Sales, Revenue, Price, Gross Profit and Competitors Analysis of Major Market) from 2015-2026
Table of Contents
Global Oncology Biosimilar Market Analysis 2020, With Top Companies, Production, Revenue, Consumption, Price and Growth Rate
1 Market Scope
1.1 Product Details and Introduction
1.1.1 Lung Cancer -Product Introduction and Major Manufacturers
1.1.2 Colorectal Cancer -Product Introduction and Major Manufacturers
1.1.3 Cervical Cancer -Product Introduction and Major Manufacturers
1.1.4 Breast Cancer -Product Introduction and Major Manufacturers
1.1.5 Kidney Cancer -Product Introduction and Major Manufacturers
1.1.6 Stomach Cancer -Product Introduction and Major Manufacturers
1.1.7 Brain Cancer -Product Introduction and Major Manufacturers
1.1.8 Others -Product Introduction and Major Manufacturers
1.2 Market Snapshot
1.2.1 Major Companies Overview
1.2.2 Market Concentration
1.2.3 Six-Year Compound Annual Growth Rate (CAGR)
2 Global Oncology Biosimilar Market Assessment, by Segmentation
2.1 Type Breakdown Estimates & Forecast, Sales Volume (2015-2026)
2.2 Type Breakdown Estimates & Forecast, Sales Value (2015-2026)
2.3 Application Breakdown Estimates & Forecast, by Application (2015-2026)
3 Regional Market Analysis
3.1 China Oncology Biosimilar Market
3.1.1 Top Companies leading Oncology Biosimilar Development in China (2015-2020)
3.1.2 Sales Value of Major Company in China Market (2015-2020)
3.1.3 China Oncology Biosimilar Price (USD/Unit), by Type (2019-2020)
3.1.4 Sales in China Market, by Type (2015-2026)
3.2 EU Oncology Biosimilar Market
3.2.1 Top Companies leading Oncology Biosimilar Development in EU (2015-2020)
3.2.2 Sales Value of Major Company in EU Market (2015-2020)
3.2.3 EU Oncology Biosimilar Price (USD/Unit), by Type (2019-2020)
3.2.4 Sales in EU Market, by Type (2015-2026)
3.3 USA Oncology Biosimilar Market
3.3.1 Top Companies leading Oncology Biosimilar Development in USA (2015-2020)
3.3.2 Sales Value of Major Company in USA Market (2015-2020)
3.3.3 USA Oncology Biosimilar Price (USD/Unit), by Type (2019-2020)
3.3.4 Sales in USA Market, by Type (2015-2026)
3.4 Japan Oncology Biosimilar Market
3.4.1 Top Companies leading Oncology Biosimilar Development in Japan (2015-2020)
3.4.2 Sales Value of Major Company in Japan Market (2015-2020)
3.4.3 Japan Oncology Biosimilar Price (USD/Unit), by Type (2019-2020)
3.4.4 Sales in Japan Market, by Type (2015-2026)
3.5 India Oncology Biosimilar Market
3.5.1 Top Companies leading Oncology Biosimilar Development in India (2015-2020)
3.5.2 Sales Value of Major Company in India Market (2015-2020)
3.5.3 India Oncology Biosimilar Price (USD/Unit), by Type (2019-2020)
3.5.4 Sales in India Market, by Type (2015-2026)
3.6 Southeast Asia Oncology Biosimilar Market
3.6.1 Top Companies leading Oncology Biosimilar Development in Southeast Asia (2015-2020)
3.6.2 Sales Value of Major Company in Southeast Asia Market (2015-2020)
3.6.3 Southeast Asia Oncology Biosimilar Price (USD/Unit), by Type (2019-2020)
3.6.4 Sales in Southeast Asia Market, by Type (2015-2026)
3.7 South America Oncology Biosimilar Market
3.7.1 Top Companies leading Oncology Biosimilar Development in South America (2015-2020)
3.7.2 Sales Value of Major Company in South America Market (2015-2020)
3.7.3 South America Oncology Biosimilar Price (USD/Unit), by Type (2019-2020)
3.7.4 Sales in South America Market, by Type (2015-2026)
4 Value Chain (Impact of COVID-19)
4.1 Oncology Biosimilar Value Chain Analysis
4.1.1 Upstream
4.1.2 Downstream
4.2 COVID-19 Impact on Oncology Biosimilar Industry
4.2.1 Industrial Policy Issued Under the Epidemic Situation
4.3 Cost-Under the Epidemic Situation
4.3.1 Cost of Raw Material
4.4 Channel Analysis
4.4.1 Distribution Channel-Under the Epidemic Situation
4.4.2 Distributors
5 Regional Market Forecast (2021-2026)
5.1 Global Oncology Biosimilar Sales and Growth Rate (2021-2026)
5.2 Global Oncology Biosimilar Sales Value and Growth Rate (2021-2026)
6 Oncology Biosimilar Competitive Analysis
6.1 Biocon
6.1.1 Biocon Company Profiles
6.1.2 Biocon Product Introduction
6.1.3 Biocon Oncology Biosimilar Production, Revenue (2015-2020)
6.1.4 SWOT Analysis
6.2 Celltrion Inc.
6.2.1 Celltrion Inc. Company Profiles
6.2.2 Celltrion Inc. Product Introduction
6.2.3 Celltrion Inc. Oncology Biosimilar Production, Revenue (2015-2020)
6.2.4 SWOT Analysis
6.3 Dr. Reddy's Laboratories
6.3.1 Dr. Reddy's Laboratories Company Profiles
6.3.2 Dr. Reddy's Laboratories Product Introduction
6.3.3 Dr. Reddy's Laboratories Oncology Biosimilar Production, Revenue (2015-2020)
6.3.4 SWOT Analysis
6.4 Intas Pharmaceuticals Ltd.
6.4.1 Intas Pharmaceuticals Ltd. Company Profiles
6.4.2 Intas Pharmaceuticals Ltd. Product Introduction
6.4.3 Intas Pharmaceuticals Ltd. Oncology Biosimilar Production, Revenue (2015-2020)
6.4.4 SWOT Analysis
6.5 STADA Arzneimittel AG
6.5.1 STADA Arzneimittel AG Company Profiles
6.5.2 STADA Arzneimittel AG Product Introduction
6.5.3 STADA Arzneimittel AG Oncology Biosimilar Production, Revenue (2015-2020)
6.5.4 SWOT Analysis
6.6 Pfizer Inc.
6.6.1 Pfizer Inc. Company Profiles
6.6.2 Pfizer Inc. Product Introduction
6.6.3 Pfizer Inc. Oncology Biosimilar Production, Revenue (2015-2020)
6.6.4 SWOT Analysis
6.7 Apotex Inc.
6.7.1 Apotex Inc. Company Profiles
6.7.2 Apotex Inc. Product Introduction
6.7.3 Apotex Inc. Oncology Biosimilar Production, Revenue (2015-2020)
6.7.4 SWOT Analysis
6.8 Teva Pharmaceutical Industries Ltd.
6.8.1 Teva Pharmaceutical Industries Ltd. Company Profiles
6.8.2 Teva Pharmaceutical Industries Ltd. Product Introduction
6.8.3 Teva Pharmaceutical Industries Ltd. Oncology Biosimilar Production, Revenue (2015-2020)
6.8.4 SWOT Analysis
6.9 Sandoz International GmbH
6.9.1 Sandoz International GmbH Company Profiles
6.9.2 Sandoz International GmbH Product Introduction
6.9.3 Sandoz International GmbH Oncology Biosimilar Production, Revenue (2015-2020)
6.9.4 SWOT Analysis
6.10 BIOCAD
6.10.1 BIOCAD Company Profiles
6.10.2 BIOCAD Product Introduction
6.10.3 BIOCAD Oncology Biosimilar Production, Revenue (2015-2020)
6.10.4 SWOT Analysis
6.11 Mylan
6.12 F Hoffmann-La Roche
7 Conclusion
List of Tables and Figures
Figure Product Introduction
Table Production (K Units) and Revenue (Million USD) of Major Players (2015-2020)
Figure Global Oncology Biosimilar Production Market Share of Top 5 Players
Table CAGR of Major Market (2021-2026)
Table CAGR in Terms of Production of Each Type (2015-2026)
Table CAGR in Terms of Production of Each Application (2015-2026)
Table Global Oncology Biosimilar Sales (K Unit) by Type (2015-2026)
Figure Global Oncology Biosimilar Sales (K Unit) and Growth Rate (2015-2026)
Figure Global Oncology Biosimilar Sales Market Share (%) by Type (2019 -2020)
Table Global Oncology Biosimilar Sales Value (Million USD) by Type (2015-2026)
Figure Global Oncology Biosimilar Sales Value (Million USD) and Growth Rate (2015-2026)
Figure Global Oncology Biosimilar Sales Value Market Share (%) by Type (2019-2020)
Table Global Oncology Biosimilar Sales (K Unit) by Application (2015-2026)
Table China Oncology Biosimilar Sales (K Unit) of Major Company (2015-2020)
Table China Oncology Biosimilar Sales Market Share of Major Company (2015-2020)
Table China Oncology Biosimilar Sales Value (Million USD) of Major Company (2015-2020)
Figure China Oncology Biosimilar Sales Value (Million USD) and Growth Rate (2015-2020)
Table China Oncology Biosimilar Sales Value Share of Major Company (2015-2020)
Table China Oncology Biosimilar Price (USD/Unit), by Type (2019-2020)
Table China Oncology Biosimilar Sales (Unit) by Type (2015-2026)
Figure China Oncology Biosimilar Sales (Unit) by Type (2015-2026)
Table EU Oncology Biosimilar Sales (K Unit) of Major Company (2015-2020)
Table EU Oncology Biosimilar Sales Market Share of Major Company (2015-2020)
Table EU Oncology Biosimilar Sales Value (Million USD) of Major Company (2015-2020)
Figure EU Oncology Biosimilar Sales Value (Million USD) and Growth Rate (2015-2020)
Table EU Oncology Biosimilar Sales Value Share of Major Company (2015-2020)
Table EU Oncology Biosimilar Price (USD/Unit), by Type (2019-2020)
Table EU Oncology Biosimilar Sales (Unit) by Type (2015-2026)
Figure EU Oncology Biosimilar Sales (Unit) by Type (2015-2026)
Table USA Oncology Biosimilar Sales (K Unit) of Major Company (2015-2020)
Table USA Oncology Biosimilar Sales Market Share of Major Company (2015-2020)
Table USA Oncology Biosimilar Sales Value (Million USD) of Major Company (2015-2020)
Figure USA Oncology Biosimilar Sales Value (Million USD) and Growth Rate (2015-2020)
Table USA Oncology Biosimilar Sales Value Share of Major Company (2015-2020)
Table USA Oncology Biosimilar Price (USD/Unit), by Type (2019-2020)
Table USA Oncology Biosimilar Sales (Unit) by Type (2015-2026)
Figure USA Oncology Biosimilar Sales (Unit) by Type (2015-2026)
Table Japan Oncology Biosimilar Sales (K Unit) of Major Company (2015-2020)
Table Japan Oncology Biosimilar Sales Market Share of Major Company (2015-2020)
Table Japan Oncology Biosimilar Sales Value (Million USD) of Major Company (2015-2020)
Figure Japan Oncology Biosimilar Sales Value (Million USD) and Growth Rate (2015-2020)
Table Japan Oncology Biosimilar Sales Value Share of Major Company (2015-2020)
Table Japan Oncology Biosimilar Price (USD/Unit), by Type (2019-2020)
Table Japan Oncology Biosimilar Sales (Unit) by Type (2015-2026)
Figure Japan Oncology Biosimilar Sales (Unit) by Type (2015-2026)
Table India Oncology Biosimilar Sales (K Unit) of Major Company (2015-2020)
Table India Oncology Biosimilar Sales Market Share of Major Company (2015-2020)
Table India Oncology Biosimilar Sales Value (Million USD) of Major Company (2015-2020)
Figure India Oncology Biosimilar Sales Value (Million USD) and Growth Rate (2015-2020)
Table India Oncology Biosimilar Sales Value Share of Major Company (2015-2020)
Table India Oncology Biosimilar Price (USD/Unit), by Type (2019-2020)
Table India Oncology Biosimilar Sales (Unit) by Type (2015-2026)
Figure India Oncology Biosimilar Sales (Unit) by Type (2015-2026)
Table Southeast Asia Oncology Biosimilar Sales (K Unit) of Major Company (2015-2020)
Table Southeast Asia Oncology Biosimilar Sales Market Share of Major Company (2015-2020)
Table Southeast Asia Oncology Biosimilar Sales Value (Million USD) of Major Company (2015-2020)
Figure Southeast Asia Oncology Biosimilar Sales Value (Million USD) and Growth Rate (2015-2020)
Table Southeast Asia Oncology Biosimilar Sales Value Share of Major Company (2015-2020)
Table Southeast Asia Oncology Biosimilar Price (USD/Unit), by Type (2019-2020)
Table Southeast Asia Oncology Biosimilar Sales (Unit) by Type (2015-2026)
Figure Southeast Asia Oncology Biosimilar Sales (Unit) by Type (2015-2026)
Table South America Oncology Biosimilar Sales (K Unit) of Major Company (2015-2020)
Table South America Oncology Biosimilar Sales Market Share of Major Company (2015-2020)
Table South America Oncology Biosimilar Sales Value (Million USD) of Major Company (2015-2020)
Figure South America Oncology Biosimilar Sales Value (Million USD) and Growth Rate (2015-2020)
Table South America Oncology Biosimilar Sales Value Share of Major Company (2015-2020)
Table South America Oncology Biosimilar Price (USD/Unit), by Type (2019-2020)
Table South America Oncology Biosimilar Sales (Unit) by Type (2015-2026)
Figure South America Oncology Biosimilar Sales (Unit) by Type (2015-2026)
Figure Value Chain Structure of Oncology Biosimilar
Table Value Chain
Table Key Suppliers of Raw Material/Components
Table Key Downstream Customer in Each Application Field
Table Industry News List of Oncology Biosimilar
Figure Cost Structure of Oncology Biosimilar in 2020
Table Distributors/Traders List
Table Regional Market Sales (K Unit) (2021-2026)
Table Regional Market Sales Share (2021-2026)
Figure Global Oncology Biosimilar Sales (Unit), Growth Rate & Market Share (2021-2026)
Table Regional Market Sales Value (Million USD) (2021-2026)
Table Regional Market Sales Value Share (2021-2026)
Figure Global Oncology Biosimilar Sales Value (Million USD), Growth Rate & Market Share (2021-2026)
Table Biocon Profiles
Table Biocon Oncology Biosimilar Product Introduction
Table Biocon Oncology Biosimilar Sales (Unit), Sales Value (Million USD), Price (USD/Unit) and Gross Profit (2015-2020)
Figure Biocon SWOT Analysis
Table Celltrion Inc. Profiles
Table Celltrion Inc. Oncology Biosimilar Product Introduction
Table Celltrion Inc. Oncology Biosimilar Sales (Unit), Sales Value (Million USD), Price (USD/Unit) and Gross Profit (2015-2020)
Figure Celltrion Inc. SWOT Analysis
Table Dr. Reddy's Laboratories Profiles
Table Dr. Reddy's Laboratories Oncology Biosimilar Product Introduction
Table Dr. Reddy's Laboratories Oncology Biosimilar Sales (Unit), Sales Value (Million USD), Price (USD/Unit) and Gross Profit (2015-2020)
Figure Dr. Reddy's Laboratories SWOT Analysis
Table Intas Pharmaceuticals Ltd. Profiles
Table Intas Pharmaceuticals Ltd. Oncology Biosimilar Product Introduction
Table Intas Pharmaceuticals Ltd. Oncology Biosimilar Sales (Unit), Sales Value (Million USD), Price (USD/Unit) and Gross Profit (2015-2020)
Figure Intas Pharmaceuticals Ltd. SWOT Analysis
Table STADA Arzneimittel AG Profiles
Table STADA Arzneimittel AG Oncology Biosimilar Product Introduction
Table STADA Arzneimittel AG Oncology Biosimilar Sales (Unit), Sales Value (Million USD), Price (USD/Unit) and Gross Profit (2015-2020)
Figure STADA Arzneimittel AG SWOT Analysis
Table Pfizer Inc. Profiles
Table Pfizer Inc. Oncology Biosimilar Product Introduction
Table Pfizer Inc. Oncology Biosimilar Sales (Unit), Sales Value (Million USD), Price (USD/Unit) and Gross Profit (2015-2020)
Figure Pfizer Inc. SWOT Analysis
Table Apotex Inc. Profiles
Table Apotex Inc. Oncology Biosimilar Product Introduction
Table Apotex Inc. Oncology Biosimilar Sales (Unit), Sales Value (Million USD), Price (USD/Unit) and Gross Profit (2015-2020)
Figure Apotex Inc. SWOT Analysis
Table Teva Pharmaceutical Industries Ltd. Profiles
Table Teva Pharmaceutical Industries Ltd. Oncology Biosimilar Product Introduction
Table Teva Pharmaceutical Industries Ltd. Oncology Biosimilar Sales (Unit), Sales Value (Million USD), Price (USD/Unit) and Gross Profit (2015-2020)
Figure Teva Pharmaceutical Industries Ltd. SWOT Analysis
Table Sandoz International GmbH Profiles
Table Sandoz International GmbH Oncology Biosimilar Product Introduction
Table Sandoz International GmbH Oncology Biosimilar Sales (Unit), Sales Value (Million USD), Price (USD/Unit) and Gross Profit (2015-2020)
Figure Sandoz International GmbH SWOT Analysis
Table BIOCAD Profiles
Table BIOCAD Oncology Biosimilar Product Introduction
Table BIOCAD Oncology Biosimilar Sales (Unit), Sales Value (Million USD), Price (USD/Unit) and Gross Profit (2015-2020)
Figure BIOCAD SWOT Analysis
Table Mylan Profiles
Table Mylan Oncology Biosimilar Product Introduction
Table Mylan Oncology Biosimilar Sales (Unit), Sales Value (Million USD), Price (USD/Unit) and Gross Profit (2015-2020)
Figure Mylan SWOT Analysis
Table F Hoffmann-La Roche Profiles
Table F Hoffmann-La Roche Oncology Biosimilar Product Introduction
Table F Hoffmann-La Roche Oncology Biosimilar Sales (Unit), Sales Value (Million USD), Price (USD/Unit) and Gross Profit (2015-2020)
Global Biologics and Biosimilars Market Growth (Status and Outlook) 2024-2030
Published: 04-Jan-2024 Price: US 3660 Onwards Pages: 147
According to our LPI (LP Information) latest study, the global Biologics and Biosimilars market size was valued at US$ 458090 million in 2023. With growing demand in downstream market, the Biologics and Biosimilars is forecast to a readjusted size of US$ 837640 million by 2030 with a CAGR of 9.0% during review period.
The research report highlights the growth potential of the global Biologics and Biosimilars market. Biologics and Biosimilars are expected to show stable growth in the futu......
Global Biosimilar Drug Market Growth 2024-2030
Published: 04-Jan-2024 Price: US 3660 Onwards Pages: 94
According to our LPI (LP Information) latest study, the global Biosimilar Drug market size was valued at US$ million in 2023. With growing demand in downstream market, the Biosimilar Drug is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during review period.
The research report highlights the growth potential of the global Biosimilar Drug market. Biosimilar Drug are expected to show stable growth in the future market. However, product differentiation, reducing cost......
Global Biologics and Biosimilars Market 2024 by Company, Regions, Type and Application, Forecast to 2030
Published: 01-Jan-2024 Price: US 3480 Onwards Pages: 147
According to our (Global Info Research) latest study, the global Biologics and Biosimilars market size was valued at USD 481830 million in 2023 and is forecast to a readjusted size of USD 842330 million by 2030 with a CAGR of 8.3% during review period.
Biologics are very specific, highly effective medicines made in living cells, and historically this was often an animal. Biologics include hormones, cytokines, growth factors, vaccines, gene and cellular therapies, fusion proteins, insulin......
Global Biosimilars Market Research Report 2023, Forecast to 2028
Published: 27-Dec-2023 Price: US 2680 Onwards Pages: 167
A biosimilar is a biologic medical product (also known as biologic) highly similar to another already approved biological medicine (the 'reference medicine').
Our market research experts provide qualitative and quantitative analysis of the market based on involving economic and non-economic factors in the same report with market value (million USD) data for each segment and sub-segment. This way, clients can achieve all their goals while taking advantage of emerging opportunities. Technol......
Global Biosimilars Professional Survey Report 2023, Forecast to 2028
Published: 27-Dec-2023 Price: US 3280 Onwards Pages: 133
A biosimilar is a biologic medical product (also known as biologic) highly similar to another already approved biological medicine (the 'reference medicine').
Our market research experts provide qualitative and quantitative analysis of the market based on involving economic and non-economic factors in the same report with market value (million USD) data for each segment and sub-segment. This way, clients can achieve all their goals while taking advantage of emerging opportunities. Technol......
Global Biosimilars Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
Published: 07-Dec-2023 Price: US 3380 Onwards Pages: 106
Market Overview of Global Biosimilars market:
According to our latest research, the global Biosimilars market looks promising in the next 5 years. As of 2022, the global Biosimilars market was estimated at USD 8203.97 million, and it's anticipated to reach USD 40650.01 million in 2028, with a CAGR of 30.57% during the forecast years.
A biosimilar product is a biologic product that is approved based on demonstrating that it is highly similar to an FDA?approved biologic product......
Global Biologics and Biosimilars Professional Survey Report 2023, Forecast to 2028
Published: 24-Nov-2023 Price: US 3280 Onwards Pages: 134
Biologics include a wide variety of products such as gene and cell therapies, therapeutic proteins, monoclonal antibodies, and vaccines. Biosimilars are highly similar to the reference product in terms of safety, purity and potency, but may have minor differences in clinically inactive components.
Our market research experts provide qualitative and quantitative analysis of the market based on involving economic and non-economic factors in the same report with market value (million USD) da......
Global Biologics and Biosimilars Market Research Report 2023, Forecast to 2028
Published: 24-Nov-2023 Price: US 2680 Onwards Pages: 160
Biologics include a wide variety of products such as gene and cell therapies, therapeutic proteins, monoclonal antibodies, and vaccines. Biosimilars are highly similar to the reference product in terms of safety, purity and potency, but may have minor differences in clinically inactive components.
Our market research experts provide qualitative and quantitative analysis of the market based on involving economic and non-economic factors in the same report with market value (million USD) da......
Global Biosimilar Monoclonal Antibodies Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
Published: 16-Nov-2023 Price: US 3380 Onwards Pages: 103
Market Overview of Global Biosimilar Monoclonal Antibodies market:
According to our latest research, the global Biosimilar Monoclonal Antibodies market looks promising in the next 5 years. As of 2022, the global Biosimilar Monoclonal Antibodies market was estimated at USD 5156.19 million, and it's anticipated to reach USD 14274.14 million in 2028, with a CAGR of 18.5% during the forecast years.
This report covers a research time span from 2018 to 2028, and presents a deep and......
SERVICES
Value for Money
We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
Ever Growing Inventory
Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
One Stop Solution
Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
Dedicated Client Engagement
Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
Saving Time and Efforts
Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
Payment Flexibility
Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
Post-Purchase Research Support
Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements.
Subscription Offers & Packages (Get in touch with us for more details -
[email protected] / +1 888 391 5441 )
- Ad Hoc
-
- Pay - as - you - go / Bucket Subscriptions
- Fixed Cost for #of reports
- Customize / Personalize as per your needs
